β2-上腺素通路对抗阿尔茨海默病:恢复认知和突触完整性
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Neural regeneration research
|October 31, 2025
概括
激活β-2上腺素受体 (β2-AR) 显示出对阿尔茨海默病治疗的前景. 它增强突触可塑性,减少神经炎症,改善线粒体功能,提供神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β oligomers,导致突触干扰,神经炎症和线粒体功能障碍.
- β-2上腺素受体 (β2-AR) 参与调节突触可塑性,神经炎症和表观遗传控制,这表明它在阿尔茨海默病中的治疗潜力.
研究的目的:
- 审查阿尔茨海默病中β2-AR介导的神经保护的基础分子机制.
- 检查β2-AR在突触可塑性,神经炎症,线粒体功能和AD相关的表观遗传调节中的作用.
主要方法:
- 对临床前研究和分子机制的审查.
- 分析β2-AR在突触功能,微质两极分化,线粒体代谢和基因表达中的作用.
主要成果:
- β2-AR激活增强长期增强,逆转粉样β诱导的突触损失,并通过cAMP/PKA/CREB通路促进神经保护性基因表达.
- β2-AR抑制了HDAC2/3,促进了对突触功能的转录重编程.
- β2-AR激活使微质两极化为抗炎性表型,增强粉样蛋白-β降解,改善线粒体的生物能学,减少氧化应激.
结论:
- β2-AR激活提供了对阿尔茨海默病病理学的多方面的神经保护.
- 向β2-AR为阿尔茨海默病提供了一个有希望的治疗策略,对认知功能和突触完整性有潜在的好处.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.通过DNA甲基化.粉样蛋白-β-β 的存在.丰富的环境 丰富的环境基斯顿基因基因基因基因基因基因基因基因基因基因基因基因基因长期增强潜力 长期增强潜力微RNAs 是一个微型RNA.微质细胞中的微质细胞线粒体中的线粒体.神经炎症是一种神经炎症.突触性可塑性 突触性可塑性更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.7K
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.5K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
535
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
535
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Long-term Depression
3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.1K
